Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CSX (CSX) downgraded to Hold from Buy at Deutsche Bank. 2. Eaton (ETN) downgraded to Hold from Buy at HSBC. 3. Amneal Pharmaceuticals (AMRX) downgraded to Underweight from Neutral at JPMorgan with analyst Christopher Schott saying while some of the challenges facing the company appear fixable, like supply penalties and plant utilization, many appear fundamental, a function of the evolving dynamics in the U.S. generics market. 4. Albemarle (ALB) downgraded to Sector Perform from Outperform at RBC Capital with analyst Arun Viswanathan saying with lithium prices falling below historical levels, global lithium suppliers may have to reduce output and wait for demand to catch up. 5. Box (BOX) downgraded to Market Perform from Outperform at JMP Securities with analyst Erik Suppiger citing concerns that after the challenging October quarter, the pipeline of the company's business has slowed. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Amneal Pharmaceuticals announced the availability of Over the Counter, or OTC, Naloxone Hydrochloride, or Naloxone HCI, Nasal Spray, USP, 4mg, following Abbreviated New Drug Application, or ANDA, approval from the FDA. Amneal's Naloxone HCI Nasal Spray, manufactured in the U.S., is a generic equivalent to OTC Narcan HCI Nasal Spray, a medication that is widely used to help treat drug overdose from opioids, including heroin, fentanyl and prescription opioid medications.